Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients:To wait and repopulate?

MLA

Eva M.M. Strijbis, et al. Longitudinal Humoral Response after SARS-CoV-2 Vaccination in Ocrelizumab Treated MS Patients:To Wait and Repopulate? Jan. 2022. EBSCOhost, https://doi.org/10.1016/j.msard.2021.103416.

APA

Eva M.M. Strijbis, A. ten Brinke, P. J. van Dam, Gertjan Wolbink, Alyssa A. Toorop, Sander W. Tas, Laura Y Kummer, Niels J. M. Verstegen, A. G. Volkers, Z.L.E. van Kempen, Mark Löwenberg, S. M. van Ham, Taco W. Kuijpers, T. Rispens, Joep Killestein, Laura Boekel, Luuk Wieske, Filip Eftimov, Maurice Steenhuis, … Eileen W Stalman. (2022). Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients:To wait and repopulate? https://doi.org/10.1016/j.msard.2021.103416

Chicago

Eva M.M. Strijbis, A. ten Brinke, P. J. van Dam, Gertjan Wolbink, Alyssa A. Toorop, Sander W. Tas, Laura Y Kummer, et al. 2022. “Longitudinal Humoral Response after SARS-CoV-2 Vaccination in Ocrelizumab Treated MS Patients:To Wait and Repopulate?,” January. doi:10.1016/j.msard.2021.103416.